Gut microbiota in type 2 diabetes mellitus: mechanistic links between dysbiosis, insulin resistance, and chronic low-grade inflammation

Category	Detail
Condition
Key Mechanisms	Dysbiosis, increased intestinal permeability, inflammatory cytokine production, disrupted insulin signaling pathways, TLR4/MyD88/NF-κB activation.
Target Population
Care Setting

Dysbiosis leads to reduced butyrate-producing bacteria (e.g., Faecalibacterium prausnitzii) and increased opportunistic pathogens.
Increased intestinal permeability facilitates lipopolysaccharide translocation, activating inflammatory pathways.
Short-chain fatty acids (SCFAs) are crucial for insulin sensitivity and are diminished in T2DM.
Dysregulated bile acid metabolism contributes to insulin resistance and metabolic inflammation.
Chronic low-grade inflammation is linked to persistent insulin resistance and β-cell failure.

Consider microbiome-informed treatment interventions targeting metabolic pathways, such as dietary changes and probiotics.

Adults diagnosed with Type 2 Diabetes Mellitus.

Focus on restoring gut microbiota balance and enhancing SCFA production.

Incorporate dietary interventions to promote beneficial gut microbiota, supported by clinical evidence.
Monitor and manage inflammatory markers in T2DM patients.
Utilize probiotics or prebiotics as adjunct therapies to improve metabolic outcomes, with references to studies.

Clinical Scorecard: The Role of Gut Microbiota in Type 2 Diabetes Mellitus: Understanding the Connections Among Dysbiosis, Insulin Resistance, and Chronic Inflammation